Thanks. Do you think payers will favor reimbursing gammagard vs. others in that scenario?
I was also wondering if the results are positive but treatment effect is marginal if insurers will try to make patients use other treatments (like aricept and namenda).
If IVIG works and another therapy works (e.g bapineuzumab), then there will be less of a mess. If IVIG works and nothing else on the horizon, then it will be a full blown shit show.